medroxyprogesterone 17 acetate

Summary

Summary: A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.

Top Publications

  1. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
  2. ncbi Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial
    Sally A Shumaker
    Department of Public Health Sciences, Wake Forest University Health Sciences, Winston Salem, NC 27104, USA
    JAMA 289:2651-62. 2003
  3. ncbi Provision of DMPA by community health workers: what the evidence shows
    Shawn Malarcher
    Office of Population and Reproductive Health, Bureau for Global Health, USAID, Washington, DC 20523 3600, USA
    Contraception 83:495-503. 2011
  4. pmc Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling
    Charles S Morrison
    Behavioral and Biomedical Research Division, Family Health International, Research Triangle Park, North Carolina 27709, USA
    AIDS 24:1778-81. 2010
  5. pmc Provision of injectable contraceptives in Ethiopia through community-based reproductive health agents
    Ndola Prata
    University of California at Berkeley, School of Public Health, 229 University Hall, Berkeley, CA 94720 6390, United States of America
    Bull World Health Organ 89:556-64. 2011
  6. ncbi Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women
    Ludo Lavreys
    Department of Epidemiology, Medicine, and Biostatistics, University of Washington, Seattle, Washington 98104 2499, USA
    J Infect Dis 189:303-11. 2004
  7. pmc Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection
    Rodolfo D Vicetti Miguel
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA
    J Immunol 189:3449-61. 2012
  8. ncbi Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial
    David D Waters
    Division of Cardiology, Room 5G1, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
    JAMA 288:2432-40. 2002
  9. ncbi Hormonal contraception and the risk of HIV acquisition among women in South Africa
    Charles S Morrison
    FHI 360, Durham, North Carolina 27713, USA
    AIDS 26:497-504. 2012
  10. ncbi Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
    Deborah Grady
    Department of Epidemiology and Biostatistics, University of California, San Francisco, 74 New Montgomery St, Suite 600, San Francisco, CA 94105, USA
    JAMA 288:49-57. 2002

Detail Information

Publications272 found, 100 shown here

  1. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
    ..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
  2. ncbi Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial
    Sally A Shumaker
    Department of Public Health Sciences, Wake Forest University Health Sciences, Winston Salem, NC 27104, USA
    JAMA 289:2651-62. 2003
    ..On July 8, 2002, the study drugs, estrogen plus progestin, in the Women's Health Initiative (WHI) trial were discontinued because of certain increased health risks in women receiving combined hormone therapy...
  3. ncbi Provision of DMPA by community health workers: what the evidence shows
    Shawn Malarcher
    Office of Population and Reproductive Health, Bureau for Global Health, USAID, Washington, DC 20523 3600, USA
    Contraception 83:495-503. 2011
    ..This article synthesizes evidence on the feasibility, safety and effectiveness of community-based delivery of the injectable contraceptive depot-medroxyprogesterone acetate (DMPA)...
  4. pmc Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling
    Charles S Morrison
    Behavioral and Biomedical Research Division, Family Health International, Research Triangle Park, North Carolina 27709, USA
    AIDS 24:1778-81. 2010
    ..Also, young (18-24 years) but not older women who used DMPA and COCs were at increased HIV risk...
  5. pmc Provision of injectable contraceptives in Ethiopia through community-based reproductive health agents
    Ndola Prata
    University of California at Berkeley, School of Public Health, 229 University Hall, Berkeley, CA 94720 6390, United States of America
    Bull World Health Organ 89:556-64. 2011
    ..To determine whether community-based health workers in a rural region of Ethiopia can provide injectable contraceptives to women with similar levels of safety, effectiveness and acceptability as health extension workers (HEWs)...
  6. ncbi Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women
    Ludo Lavreys
    Department of Epidemiology, Medicine, and Biostatistics, University of Washington, Seattle, Washington 98104 2499, USA
    J Infect Dis 189:303-11. 2004
    ..These findings suggest that, in women, the use of DMPA and the presence of GUD during the early phase of HIV-1 infection may influence the natural course of infection...
  7. pmc Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection
    Rodolfo D Vicetti Miguel
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA
    J Immunol 189:3449-61. 2012
    ..Taken together, our results reveal that the administration of MPA prior to viral infection of mucosal tissue impairs DC activation, virus-specific T cell expansion, and development of virus-specific immunological memory...
  8. ncbi Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial
    David D Waters
    Division of Cardiology, Room 5G1, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
    JAMA 288:2432-40. 2002
    ..Hormone replacement therapy (HRT) and antioxidant vitamins are widely used for secondary prevention in postmenopausal women with coronary disease, but no clinical trials have demonstrated benefit to support their use...
  9. ncbi Hormonal contraception and the risk of HIV acquisition among women in South Africa
    Charles S Morrison
    FHI 360, Durham, North Carolina 27713, USA
    AIDS 26:497-504. 2012
    ....
  10. ncbi Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
    Deborah Grady
    Department of Epidemiology and Biostatistics, University of California, San Francisco, 74 New Montgomery St, Suite 600, San Francisco, CA 94105, USA
    JAMA 288:49-57. 2002
    ..However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5...
  11. pmc Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093
    D Heather Watts
    National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA
    Contraception 77:84-90. 2008
    ..We evaluated the safety and tolerability of depot medroxyprogesterone acetate (DMPA) among women on ARV...
  12. ncbi Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells
    Dominique Koubovec
    Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland 7602, South Africa
    Mol Cell Endocrinol 221:75-85. 2004
    ..The MPA-induced nuclear translocation of the glucocorticoid receptor (GR), as well as the antagonistic effects of RU486, strongly suggest that the actions of MPA in these cells are mediated at least in part via the GR...
  13. pmc Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms
    Richard P H Huijbregts
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294 2182, USA
    Endocrinology 154:1282-95. 2013
    ..The presented results suggest that MPA suppresses both innate and adaptive arms of the immune system resulting in a reduction of host resistance to invading pathogens...
  14. ncbi Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial
    Stephen R Rapp
    Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    JAMA 289:2663-72. 2003
    ..On July 8, 2002, the estrogen plus progestin therapy in the WHI trial was discontinued because of certain increased health risks for women...
  15. ncbi Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells
    Jeffrey D Bray
    Women s Health Research Institute, Wyeth Research, Collegeville, PA 19426, USA
    J Steroid Biochem Mol Biol 97:328-41. 2005
    ..This analysis demonstrates a high degree of similarity among these progestins on PR-regulated gene expression in T47D cells, suggesting a similar and fairly specific mode of action...
  16. ncbi A novel immortalized human endometrial stromal cell line with normal progestational response
    Graciela Krikun
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, P O Box 208063, New Haven, Connecticut 06520 8063, USA
    Endocrinology 145:2291-6. 2004
    ..In summary, an immortalized HESC line has been developed that is karyotypically, morphologically, and phenotypically similar to the primary parent cells, and it is a powerful and consistent resource for in vitro work...
  17. ncbi 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy
    Qian Hu
    Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China
    Int J Gynecol Cancer 22:951-9. 2012
    ..Here, we explored whether 5-aza-2'-deoxycytidine (5-aza-CdR), a demethylating agent, could enhance the susceptibility of EC cells to medroxyprogesterone acetate (MPA)...
  18. pmc Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial
    Sengeziwe Sibeko
    Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Obstet Gynecol 118:895-904. 2011
    ....
  19. ncbi Scaling up community provision of injectables through the public sector in Uganda
    Kirsten Krueger
    FHI, P O Box 13950, Research Triangle Park, NC 27709, USA
    Stud Fam Plann 42:117-24. 2011
    ..Lessons from scaling up in Uganda's public sector include recognizing the needs for ongoing assessment of support, a process to gain community "ownership," and spontaneous innovations to supplement CHW supervision...
  20. ncbi Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections
    Charles S Morrison
    Family Health International, Research Triangle Park, North Carolina 27709, USA
    Sex Transm Dis 31:561-7. 2004
    ..Several previous studies have suggested that hormonal contraception could be associated with increased risk of cervical infections. However, few high-quality prospective studies have examined this relationship...
  21. ncbi Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
    S Hulley
    University of California, San Francisco 94143, USA
    JAMA 280:605-13. 1998
    ..However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue...
  22. ncbi Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques
    Nataliya Trunova
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Virology 352:169-77. 2006
    ....
  23. ncbi Synthetic progestins used in HRT have different glucocorticoid agonist properties
    Dominique Koubovec
    Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland, Stellenbosch 7602, South Africa
    Mol Cell Endocrinol 242:23-32. 2005
    ..MPA and NET-A therefore display very different GC-like properties compared to each other and to prog, and are likely to exhibit different side effects via the GR...
  24. ncbi The effect of hormonal contraception on genital tract shedding of HIV-1
    Chia C Wang
    Department of Medicine, University of Washington, Seattle, Washington 98104 2499, USA
    AIDS 18:205-9. 2004
    ..We conducted a prospective study to determine if cervical shedding of HIV-1 increased after initiating hormonal contraception...
  25. pmc Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells
    Cecilia Proietti
    Instituto de Biología y Medicina Experimental IBYME, CONICET, Buenos Aires 1428, Argentina
    Mol Cell Biol 25:4826-40. 2005
    ..Our results have for the first time demonstrated that progestins are able to induce Stat3 transcriptional activation, which is in turn an obligatory requirement for progestin stimulation of both in vitro and in vivo breast cancer growth...
  26. ncbi Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial
    Rowan T Chlebowski
    Harbor UCLA Research and Education Institute, Torrance 90502, USA
    JAMA 289:3243-53. 2003
    ..Outstanding issues not previously addressed include characteristics of breast cancers observed among women using hormones and whether diagnosis may be influenced by hormone effects on mammography...
  27. ncbi Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial
    Sylvia Wassertheil-Smoller
    Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    JAMA 289:2673-84. 2003
    ..The Women's Health Initiative (WHI) trial of estrogen plus progestin was stopped early because of adverse effects, including an increased risk of stroke in the estrogen plus progestin group...
  28. pmc Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe
    Charles S Morrison
    Department of Clinical Sciences, Family Health International, Research Triangle Park, NC, USA
    J Acquir Immune Defic Syndr 57:157-64. 2011
    ..Previous studies report conflicting results regarding the effect of hormonal contraception on HIV disease progression...
  29. pmc Potential role of leptin expression in hepatocellular carcinoma
    S N Wang
    Division of Hepatobiliary Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    J Clin Pathol 59:930-4. 2006
    ..Obesity is associated with hepatocellular carcinoma (HCC). The association may result from the aberrant expression of adipokines...
  30. ncbi Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells
    S M Hyder
    Department of Integrative Biology and Pharmacology, University of Texas Health Science Center Houston, Houston, TX 77030, USA
    Int J Cancer 92:469-73. 2001
    ..This report demonstrates that progestins stimulate VEGF mRNA levels and raises the possibility that anti-progestins may be useful to inhibit proliferation and metastasis in some human breast cancers by blocking VEGF production...
  31. ncbi Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma
    Emanuele Naglieri
    Medical and Experimental Oncology Department, Oncology Institute, Via Amendola 209, 70126 Bari, Italy
    Anticancer Res 22:3045-51. 2002
    ..Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-alpha and MPA...
  32. ncbi Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
    Stephen Hulley
    Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, CA 94143 0560, USA
    JAMA 288:58-66. 2002
    ..The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized trial of estrogen plus progestin therapy after menopause...
  33. ncbi Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
    M Cushman
    Departments of Medicine, and Biochemistry, University of Vermont, Burlington, VT 05446, USA
    Circulation 100:717-22. 1999
    ..Because higher levels of inflammation factors predict vascular disease outcomes, the effect of hormones on these factors is of interest...
  34. pmc Characterization of a novel telomerase-immortalized human endometrial stromal cell line, St-T1b
    Annemarie Samalecos
    Endokrinologikum Hamburg, 20251 Hamburg, Germany
    Reprod Biol Endocrinol 7:76. 2009
    ..Studies into the mechanisms of decidualization are often hampered by the lack of primary ESC. Here we describe a novel immortalized human ESC line...
  35. ncbi Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate
    Grant Buchanan
    Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide Hanson Institute, Adelaide, South Australia, Australia
    Cancer Res 65:8487-96. 2005
    ..Collectively, these data suggest that reduced levels of AR or impaired AR function contribute to the failure of MPA therapy potentially due to abrogation of the inhibitory effect of AR on ER signaling...
  36. ncbi Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
    M G Shlipak
    Department of Medicine, University of California, and Veterans Affairs Medical Center, San Francisco, USA
    JAMA 283:1845-52. 2000
    ..However, few data exist on the clinical importance of Lp(a) lowering for CHD prevention. Hormone therapy with estrogen has been found to lower Lp(a) levels in women...
  37. ncbi Hormonal contraception and HIV prevalence in four African countries
    Pauline M Leclerc
    Epidemiologie des Maladies Emergentes, Institut Pasteur, 25 rue du Docteur Roux, Paris, France
    Contraception 77:371-6. 2008
    ..The HIV seroprevalence among women aged 15-24 years was compared according to their pattern of contraceptive use in four African countries: Kenya, Lesotho, Malawi and Zimbabwe...
  38. pmc Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239
    Kristina Abel
    Center for Comparative Medicine, and California National Primate Research Center, University of California at Davis, Davis, California 95616, USA
    J Infect Dis 190:1697-705. 2004
    ..6-immunized macaques. In the primate model of sexual transmission of human immunodeficiency virus, treatment with progesterone before IVAG challenge with a pathogenic virus can decrease the efficacy of a model "vaccine."..
  39. pmc Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling
    Jon Nilsen
    Department of Molecular Pharmacology and Toxicology and Program in Neuroscience, Pharmaceutical Sciences Center, University of Southern California, Los Angeles, CA 90089, USA
    Proc Natl Acad Sci U S A 100:10506-11. 2003
    ..The recent results from the Women's Health Initiative trial, which used MPA as the progestinal agent, indicate that differences between progestin formulations are crucial to health outcomes in women...
  40. ncbi Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy
    C J Kim
    Department of Internal Medicine, Chung Ang University Medical Center, Seoul, Korea
    Arch Intern Med 156:1693-700. 1996
    ..One of the possible mechanisms of this effect is the modification of lipid profiles. However, there is controversy concerning the effects on lipoprotein(a) [Lp (a)] and lipid levels of progestogens administered with estrogen...
  41. pmc Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques
    Karen Pazol
    Yerkes National Primate Research Center and the Center for Behavioral Neuroscience, Emory University, Atlanta, Georgia 30322, USA
    J Clin Endocrinol Metab 89:2998-3006. 2004
    ..The marked increase in aggression seen during MPA treatment suggests that production of negative affect may be a particularly serious side effect of MPA...
  42. ncbi A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids
    L Enk
    Department of Obstetrics and Gynecology, Sahlgrenska Hospital, , Sweden
    Horm Metab Res 24:85-9. 1992
    ..Thus our findings might indicate an adverse effect in this respect of long term treatment with these progestins, particularly with NET...
  43. ncbi Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraception
    Edgar Turner Overton
    Division of Infectious Diseases, Washington University School of Medicine, Campus Box 8051, St Louis, MO 63110 1093, USA
    Contraception 78:125-30. 2008
    ..The primary aim of this study was to characterize the potential association between DMPA use and risk of STI acquisition among HIV-infected women...
  44. pmc Use of injectable progestin contraception and risk of STI among South African women
    Audrey Pettifor
    Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
    Contraception 80:555-60. 2009
    ....
  45. ncbi Inhibition of cAMP-mediated decidualization in human endometrial stromal cells by IL-1beta and laminin
    K Mizuno
    Department of Obstetrics and Gynecology, Osaka City University Medical School, Osaka, Japan
    Horm Metab Res 31:307-10. 1999
    ..These results indicate that IL-1beta and laminin additively and mutually inhibit cAMP-mediated decidualization signals, and that they may inhibit these signals through different mechanisms...
  46. pmc Progesterone increases susceptibility and decreases immune responses to genital herpes infection
    Charu Kaushic
    Department of Pathology and Molecular Medicine, Center of Gene Therapeutics, McMaster University Health Sciences Center, Hamilton, Ontario, Canada
    J Virol 77:4558-65. 2003
    ..Animal models and vaccine strategies for sexually transmitted diseases need to consider the effect of hormone treatments on susceptibility and immune responses...
  47. ncbi Oxidative stress, lipid profile and liver functions in average Egyptian long term depo medroxy progesterone acetate (DMPA) users
    L M Faddah
    Biochemistry Departments, Faculty of Pharmacy, El Minia University, Egypt
    Molecules 10:1145-52. 2005
    ..In addition, annual re-evaluation is much more advisable despite the proven safety of the drug...
  48. ncbi Estrogen plus progestin and the risk of coronary heart disease
    JoAnn E Manson
    Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 349:523-34. 2003
    ..In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI)...
  49. ncbi Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells
    Maki Saitoh
    Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, 2 2 2 Iidanishi, Yamagata 990 9585, Japan
    Endocrinology 146:4917-25. 2005
    ....
  50. ncbi Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757]
    Sigrid Vorobjov
    Department of Epidemiology and Biostatistics, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia
    Maturitas 52:286-95. 2005
    ..To investigate treatment adherence and factors related to non-adherence in the Estonian postmenopausal hormone therapy (EPHT) trial...
  51. ncbi Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative
    Vanessa M Barnabei
    Department of Obstetrics and Gynecology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
    Obstet Gynecol 105:1063-73. 2005
    ..To estimate the effects of estrogen plus progestin (E+P) therapy on menopausal symptoms, vaginal bleeding, gynecologic surgery rates, and treatment-related adverse effects in postmenopausal women...
  52. ncbi Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells
    Tommaso Simoncini
    Molecular and Cellular Gynecological Endocrinology Laboratory, Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa 56100, Italy
    Endocrinology 145:5745-56. 2004
    ..Our findings show significant differences in the signal transduction pathways recruited by P and MPA in endothelial cells, which may have relevant clinical implications...
  53. ncbi Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease
    S L Fenton
    Division of Medical Sciences, University of Birmingham, UK
    Leukemia 17:568-75. 2003
    ..Importantly, since fibrates and MPA are inexpensive and stable with minimal-associated toxicities, we suggest that these drugs should be considered as adjuncts to currently available treatments for BL in endemic and AIDS-related disease...
  54. ncbi Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial
    Mark A Hlatky
    Stanford University School of Medicine, HRP Redwood Bldg, Room 150, Stanford, CA 94305 5405, USA
    JAMA 287:591-7. 2002
    ..Postmenopausal hormone therapy is commonly used by women for disease prevention, but its effects on quality of life have not been well documented...
  55. ncbi Spinal bone density in women using depot medroxyprogesterone contraception
    T Cundy
    Department of Medicine, The Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
    Obstet Gynecol 92:569-73. 1998
    ..To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot medroxyprogesterone acetate...
  56. ncbi Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation
    M Salatino
    Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biologia y Medicina Experimental, Consejo Nacional de Investigaciones Cientificas y Tecnicas, Buenos Aires, Argentina
    Oncogene 25:7723-39. 2006
    ..We also demonstrated that caveolin-1 is a downstream effector of MPA that is partially responsible for the stimulation of growth of breast cancer cells...
  57. ncbi Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2
    R E Hayden
    University of Birmingham, School of Biosciences, Edgbaston, Birmingham, UK
    Leukemia 23:292-304. 2009
    ..Given the known safety profiles of BEZ and MPA, our data warrant further investigation of their potential as novel therapy for CLL...
  58. ncbi Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells
    J J Brosens
    Department of Reproductive Sciences and Medicine, Imperial College of Science, Technology, and Medicine, Hammersmith Hospital, London, United Kingdom
    Endocrinology 140:4809-20. 1999
    ....
  59. ncbi Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
    M R Adams
    Comparative Medicine Clinical Research Center, Bowman Gray School of Medicine, Wake Forest University, Winston Salem, NC 27157 1040, USA
    Arterioscler Thromb Vasc Biol 17:217-21. 1997
    ..Although the mechanism(s) remains unclear, we conclude that oral CEE inhibits the initiation and progression of coronary artery atherosclerosis and that continuously administered oral MPA antagonizes this atheroprotective effect...
  60. ncbi Overview of why hormones may be an issue
    Christine Mauck
    CONRAD Arlington, VA, USA
    J Acquir Immune Defic Syndr 38:S11-2. 2005
  61. ncbi Depo medroxyprogesterone acetate (DMPA) and combined oral contraceptives and cervical carcinoma in-situ in women aged 50 years and under
    C Hoyo
    Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    West Indian Med J 53:406-12. 2004
    ..4, 95% CI: 0.7, 3.1). These results suggest that if hormonal contraceptive use confers any risk of CIS, it is confined to long-term users. Increased risk in some groups, however, warrant further study...
  62. ncbi Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes
    C M Bamberger
    Department of Medicine, University Hospital Eppendorf, Hamburg, Germany
    J Clin Endocrinol Metab 84:4055-61. 1999
    ..Because of its dissociative GC activity, MPA is a highly promising substance for the treatment of inflammatory/autoimmune states...
  63. ncbi Involvement of EGF in medroxyprogesterone acetate (MPA)-induced mammary gland hyperplasia and its role in MPA-induced mammary tumors in BALB/c mice
    A Molinolo
    Instituto de Biologia y Medicina Experimental, Academia Nacional de Medicina, Buenos Aires, Argentina
    Cancer Lett 126:49-57. 1998
    ..It can be concluded that although EGF plays an important role in MPA-induced mammary carcinogenesis, it is not necessary in PD tumor growth...
  64. ncbi Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells
    Jianbo Wu
    Dalton Cardiovascular Research Center and the Department of Biomedical Sciences, University of Missouri Columbia, Columbia, Missouri 65211, USA
    Mol Endocrinol 19:312-26. 2005
    ....
  65. pmc The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells
    Radhika P Ghatge
    University of Colorado Health Sciences Center, Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, Denver, Colorado, USA
    Breast Cancer Res 7:R1036-50. 2005
    ..Is this risk due to its progestational or androgenic properties? To address this, we assessed the transcriptional effects of MPA as compared with those of progesterone and dihydrotestosterone (DHT) in human breast cancer cells...
  66. pmc Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239
    Meritxell Genesca
    Center for Comparative Medicine, University of California, Davis, CA 95616, USA
    J Med Primatol 36:266-75. 2007
    ..Progesterone administration prior to intravaginal challenge with pathogenic SIVmac239 decreases the protective efficacy of live attenuated vaccines in rhesus macaques...
  67. ncbi Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate alpha-ENaC and sgk1 expression in renal collecting duct epithelia
    Christie P Thomas
    Division of Nephrology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242 1081, USA
    Am J Physiol Renal Physiol 290:F306-12. 2006
    ..The activation of steroid receptors such as GR can explain the apparent glucocorticoid effects of MPA, independent of PR activation...
  68. ncbi Prospective study of hormonal contraception and women's risk of HIV infection in South Africa
    Landon Myer
    Infectious Diseases Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
    Int J Epidemiol 36:166-74. 2007
    ..We investigated associations between HIV incidence and use of combined oral contraceptives (COC), norethindrone enanthate (NET-EN) or depot medroxyprogesterone acetate (DMPA) in a cohort of South African women...
  69. ncbi Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques
    E Isaksson
    Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Breast Cancer Res Treat 79:233-9. 2003
    ..The results suggest that hormonal treatments have a different influence on the PRA/PRB balance in the breast...
  70. pmc Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial
    C Focan
    , Belgium
    Br J Cancer 85:1-8. 2001
    ..For both NN and NP patients, differences in overall survivals observed in older women with a shorter follow-up, were no longer detected...
  71. ncbi The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells
    Elizabeth A Krämer
    Section of Endocrinology and Menopause, University Womens Hospital, Tuebingen, Germany
    Menopause 12:468-74. 2005
    ....
  72. ncbi Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques
    J M Cline
    Department of Comparative Medicine, Bowman Gray School of Medicine of Wake Forest University, Winston Salem, North Carolina 27157 1040, USA
    Breast Cancer Res Treat 48:221-9. 1998
    ....
  73. ncbi Relationship between progesterone receptor level in endometrium and bleeding pattern in depot medroxyprogesterone acetate users
    Pichai Chotnopparatpattara
    Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
    J Med Assoc Thai 86:172-7. 2003
    ..05). In conclusion, after a second dose of DMPA, subjects with amenorrhea had a higher stromal PR score than those with uterine bleeding...
  74. ncbi Regulation of progesterone receptor messenger ribonucleic acid by progestin in human endometrial stromal cells
    L Tseng
    Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, 11794, USA
    Biol Reprod 57:1360-6. 1997
    ..The up-regulation of PR by progestin may be mediated in part by progestin-induced endometrial stromal cell factors such as estrogen and insulin-like growth factor-I, both of which stimulated the PR-A and PR-B mRNA in stromal cells...
  75. ncbi [Effects of hormonal replacement therapy on breast density in postmenopausal women]
    T Bisanti
    Dipartimento di Scienze Ginecologiche, Perinatologia, Puericultura, Universita degli Studi di Roma La Sapienza, Roma, Italy
    Minerva Ginecol 56:125-30. 2004
    ..The aim of this non randomised prospective study was to evaluate the effects of HRT and Tibolone on breast density in postmenopausal women...
  76. ncbi Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal women
    Mitsuhiro Sanada
    Department of Obstetrics and Gynecology, Faculty of Medicine, Hiroshima University, Hiroshima, Japan
    Menopause 9:360-6. 2002
    ..We investigated whether low-dose medroxyprogesterone acetate (MPA) combined with oral estrogen had adverse effects on endothelial function compared with oral estrogen alone in postmenopausal women with mild hypercholesterolemia...
  77. ncbi Comparison of the effects of tibolone and estrogen replacement therapy on echocardiographic basic cardiac functions in post-menopausal women: a randomized placebo controlled study
    Omur Taskin
    Department of Obstetrics Gynecology, Division of Reprod Endoc, Akdeniz University School of Medicine, Antalya, Turkey
    Maturitas 48:354-9. 2004
    ..This study is designed to investigate and compare the effects of synthetic steroid tibolone and HRT on systolic and diastolic heart functions in post-menopausal women...
  78. ncbi B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram
    Hiroaki Kawano
    Department of Cardiovascular Medicine, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan
    Menopause 15:352-6. 2008
    ..We sought to examine the effects of hormone therapy (HT) on myocardial function and cardiac natriuretic peptides in postmenopausal women with chest pain and a normal coronary angiogram...
  79. ncbi Estrogen replacement therapy among postmenopausal women and its effects on signs and symptoms of temporomandibular disorders
    Aysen Nekora-Azak
    University of Istanbul, Faculty of Dentistry, Department of Maxillofacial Prosthodontics, Istanbul, Turkey
    Cranio 26:211-5. 2008
    ..There was no association between the use of postmenopausal hormones and the signs and symptoms of TMD in this study...
  80. ncbi No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years
    Risto Erkkola
    Turku University Hospital, Turku, Finland
    J Br Menopause Soc 10:9-13. 2004
    ..Mammography was performed at baseline and at 24-month intervals thereafter. Adverse events were assessed throughout the study...
  81. ncbi [Differential effects on serum IGF-1 of tibolone (5 mg/day) vs combined continuous estrogen/progestagen in post menopausal women]
    Arnaldo Porcile
    Departamentos de Obstetricia y Ginecología y de Medicina, Facultad de Medicina Campus Oriente, Universidad de Chile, Santiago, Chile
    Rev Med Chil 131:1151-6. 2003
    ..Tibolone has estrogenic, androgenic and progestational effects and is used in post menopausal women. It apparently has weaker effects on endometrial proliferation and mammary stimulation than conventional hormone replacement therapy...
  82. ncbi Hormone therapy and ophthalmic artery blood flow changes in women with primary open-angle glaucoma
    Cesare Battaglia
    III Department of Obstetrics and Gynecology, University of Bologna, Bologna, Italy
    Menopause 11:69-77. 2004
    ..To compare the effects of hormone therapy (HT) on plasma viscosity and Doppler flow parameters in normal, healthy, postmenopausal women and in women with normal-tension and chronic, open-angle glaucoma...
  83. ncbi Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women
    Tatjana E Vogelvang
    project Aging Women and the Institute for Cardiovascular Research Vrije Universiteit ICaR VU Department of Obstetrics and Gynecology, Vrije University Medical Center, Amsterdam, The Netherlands
    Menopause 11:110-5. 2004
    ..The aim of this study was to compare the long-term effects of two dosages of raloxifene with oral hormone therapy (HT; conjugated equine estrogens combined with medroxyprogesterone acetate) on procarboxypeptidase U...
  84. ncbi Effect of postmenopausal hormone replacement therapy on cardiovascular performance
    Kurtulus Ozdemir
    Cardiology Department, Medical Faculty, Selcuk University, Aybüke Sitesi 83 14, 42080 Selçuklu, Konya, Turkey
    Maturitas 47:107-13. 2004
    ..This study was planned to investigate the long-term effects of HRT on cardiac functions and exercise performance...
  85. ncbi HT and WHI: the baby and the bathwater
    F W Danby
    Climacteric 7:112. 2004
  86. ncbi Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women
    Ailish G Nugent
    Garvan Institute of Medical Research, Department of Endocrinology, St Vincent s Hospital, Darlinghurst, NSW, Australia
    Clin Endocrinol (Oxf) 59:690-8. 2003
    ..As progestogens attenuate the effects of oestrogen on circulating lipid levels according to their androgenic properties, we have investigated the impact of progestogen types on the hepatic endocrine effects of oestrogen...
  87. ncbi Progestins initiate adverse events of menopausal estrogen therapy
    T Thomas
    College of Medicine, University of South Florida, Tampa, Florida 34677, USA
    Climacteric 6:293-301. 2003
    ..We investigated the role of synthetic progestins in initiating the adverse events associated with estrogen therapy...
  88. ncbi Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women
    Bora Cengiz
    Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
    Maturitas 46:301-6. 2003
    ..The effect of hormone replacement therapy (HRT) on serum levels of tumor markers is barely defined. The aim of this study was to evaluate the effect of HRT on levels of tumor markers CA 125, CA 15-3, CA 19-9, CEA and alpha-FP...
  89. ncbi Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen
    M C P Rees
    Nuffield Department of Obstetrics and Gynaecology, Women s Centre, John Radcliffe Hospital, Oxford, UK
    Climacteric 7:23-32. 2004
    ..Two randomized comparative multicenter studies were conducted to establish the endometrial safety and tolerability of a triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate (E2V/MPA) therapy regimen...
  90. ncbi Ultrastructure study of postmenopausal endometria of tibolone, conjugated estrogen + medroxyprogesterone acetate and tamoxifen users
    Tuncay Nas
    Department of Obstetrics and Gynecology, Faculty of Medicine, Gazi University, 06510 Besevler, Ankara, Turkey
    Saudi Med J 28:1917-9. 2007
  91. ncbi A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen
    L A Mattsson
    Sahlgrenska University Hospital, Department of Obstetrics and Gynecology, Gothenburg, Sweden
    Climacteric 7:59-69. 2004
    ..To compare bleeding control, efficacy and safety of two dose-ranging continuous combined hormone replacement therapy (HRT) regimens with those of a conventional continuous combined HRT...
  92. ncbi Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene
    G Christodoulakos
    2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, V Sofias 76, GR 11528, Athens, Greece
    Maturitas 50:321-30. 2005
    ..To assess endogenous androgen and insulin resistance status in postmenopausal women receiving continuous combined hormone therapy (HT), tibolone, raloxifene or no therapy...
  93. ncbi Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women
    Mehmet Yilmazer
    Department of Obstetrics and Gynecology, Afyon Kocatepe University, Faculty of Medicine, Afyon, Turkey
    Hum Reprod 18:1531-5. 2003
    ..In this cross-sectional study, serum C3, C4, IgG and IgM levels were evaluated in healthy post-menopausal women receiving two different short-term HRT regimens, and in untreated women...
  94. ncbi [Profiles of irregular bleeding induced by low-dose hormone therapy and Chinese formulated herbs products]
    Shao Hai Wang
    Department of Obstetrics and Gynecology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28:256-61. 2006
    ..To compare profiles and related factors of irregular bleeding induced by different types of low-dose hormone therapy (HT) and a Chinese formulated herbs products...
  95. pmc Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women
    Hong Sook Ko
    Department of Internal Medicine, College of Medicine, Chung Ang University Seoul, Korea
    Korean J Intern Med 20:33-9. 2005
    ..However, the results of randomized controlled trials have been discouraging. We attempted to evaluate the influence of overweight, a frequent risk factor for coronary artery disease, on the lipid-modifying effects of HRT...
  96. ncbi Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs
    H M J Werner
    Departments of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, Enschede, The Netherlands
    Climacteric 8:294-9. 2005
    ..e. MCF-7 and T-47D) and -negative (ER-) (i.e. MDA-MB-231) human breast cancer cells in vitro...
  97. ncbi The effect of postmenopausal hormone therapy with or without folic acid supplementation on serum homocysteine level
    A Toprak
    Department of Cardiology, Marmara University School of Medicine, Istanbul, Turkey
    Climacteric 8:279-86. 2005
    ..Additionally, a non-randomized control group with no treatment was included...
  98. ncbi Hormone use and patient concerns after the findings of the Women's Health Initiative
    Sharon J Rolnick
    HealthPartners Research Foundation, Minneapolis, MN 55440 1524, USA
    Menopause 12:399-404. 2005
    ..To assess behaviors and concerns related to hormone therapy after the findings of the Women's Health Initiative (WHI)...
  99. ncbi Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding
    Gazi Yildirim
    Zeynep Kamil Women and Children s Education and Research Hospital, Istanbul, Turkey
    Arch Gynecol Obstet 273:268-73. 2006
    ..625 mg conjugated equine estrogen (CEE) + 2.5 mg medroxyprogesterone acetate (MPA) and 1 mg 17beta estradiol (E2) + 0.5 mg norethindrone acetate (NETA), on endometrial histopathology and postmenopausal uterine bleeding...
  100. ncbi Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy
    Cristiana Vitale
    Cardiovascular Research Unit Department of Medical Sciences, Fondazione San Raffaele IRCCS Roma, Tosinvest Sanita, Roma, Italy
    Menopause 12:552-8. 2005
    ....
  101. ncbi Progestogens: effects on clinical and biochemical parameters in postmenopausal women
    David F Archer
    Menopause 12:484-7. 2005

Research Grants63

  1. Innate immunity predictors of HIV: the role of contraception, pregnancy and HSV-2
    Charles Morrison; Fiscal Year: 2013
    ..This research provides a unique opportunity to elucidate and validate the complex associations between endogenous and exogenous hormones, HSV-2 and HIV-1 through analysis of underlying shared biological mechanisms. ..
  2. Variations in Hormones During Menopause: Effects on Cognitive and Brain Aging
    Heather A Bimonte-Nelson; Fiscal Year: 2013
    ..This work will yield insight into cognitive effects of the menopause transition, variations in menopause type and HTs, and related mechanisms. ..
  3. Biosignature of the endometrium in women with endometriosis
    Neil Sidell; Fiscal Year: 2010
    ....
  4. MOLECULAR MECHANISM OF LEIOMYOMA GROWTH AND REGRESSION
    GREGORY SCOTT SCHULTZ; Fiscal Year: 2011
    ..This proposal will investigate how fibroids are developed and grow, and ways to prevent them, including their symptoms. ..
  5. Quantification of Immune Cells in Women Using Contraception
    SHARON LYNELLE ACHILLES; Fiscal Year: 2013
    ....
  6. A Randomized Trial of the Copper IUD versus DMPA for HIV Prevention in Women
    Helen Rees; Fiscal Year: 2012
    ....
  7. Factors That Affect Endometrial Immunity: Implications for HIV Infection
    Joseph C Chen; Fiscal Year: 2012
    ..The achievement of these goals can greatly contribute to the field of reproductive biology and overall reproductive health. ..
  8. Modulation of Hormonal and Systemic Immunity by Hormonal Contraceptive Use
    Thomas L Cherpes; Fiscal Year: 2013
    ....
  9. Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue
    Natalia Teleshova; Fiscal Year: 2013
    ..Furthermore, we will address the mechanism of progestin/progesterone action at both sites by focusing on the immune environment and potentially identify underlying factors that influence a woman's susceptibility to HIV infection. ..
  10. Evaluation of the immunologic and genital tract changes among Malawian women
    Jennifer Tang; Fiscal Year: 2013
    ..This trial will be submitted by Dr. Tang as an R01 application before the end of the 4-year career development award period. ..
  11. Evaluation of a subunit Chlamydia trachomatis vaccine in Rhesus Macaques
    Luis M de la Maza; Fiscal Year: 2011
    ..vag. challenge. Decreasing the incidence and prevalence of CT infections with a vaccine would have a major health impact worldwide. ..
  12. Hormone Therapy and Cognitive Aging in Older and Younger Postmenopausal Women: E
    Sally Shumaker; Fiscal Year: 2011
    ..WHIMS-Y tests the [unreadable]window of opportunity[unreadable] hypothesis that HT shortly after menopause will confer benefit to later cognitive health. ..
  13. The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK
    CRAIG WALTER HENDRIX; Fiscal Year: 2013
    ....
  14. Hormonal Contraception and HIV Acquisition: An IPD Meta-analysis
    Charles Morrison; Fiscal Year: 2012
    ....
  15. Prevention of HIV transmission/acquisition through informed contraceptive choice
    Danny J Schust; Fiscal Year: 2013
    ....
  16. ENDOMETRIAL VEGF: ENDOCRINE REGULATION OF ANGIOGENESIS
    Robert Taylor; Fiscal Year: 1999
    ..An understanding of the cellular expression of VEGF and the endocrine regulation of endometrial angiogenesis should provide new targets to improve the acceptability of these effective contraceptive devices. ..
  17. CONFIRMATION STUDIES OF BLOOD BASED BIOMARKERS OF RISK FOR BREAST CANCER
    Samir M Hanash; Fiscal Year: 2012
    ..The proposed project has the potential to contribute clinically relevant breast cancer biomarkers to identify women at increased risk and to clarify breast cancer risk associated with postmenopausal hormone therapy. ..
  18. Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera
    Zhiheng Pei; Fiscal Year: 2013
    ..The results of our studies will provide a better understanding of how DMPA modulates immunologic responses and microbiomes, thereby informing the design of effective HIV prevention strategies. ..
  19. HORMONAL CONTRACEPTON & RISK OF HIV ACQUISITION
    MORRISON CHARLES; Fiscal Year: 2010
    ..abstract_text> ..
  20. CGMP PROTEIN KINASE IN PREGNANT MYOMETRIUM
    Trudy Cornwell; Fiscal Year: 2000
    ..Clarification of the regulation of cG-kinase by progesterone will provide insight into the design of tocolytic therapies based on nitric oxide and cGMP actions. ..
  21. OVARIAN STEROIDS AND CALCIUM HOMEOSTASIS
    NEIL BRESLAU; Fiscal Year: 1991
    ..The potential ability of oral contraceptives (as an adjunctive agent in treating hirsutism) and the nonsteroidal estrogen antagonist tamoxifen (as an adjunctive agent in treating breast cancer) to protect bone will be evaluated...
  22. INITIATING CONTRACEPTION IN AN STD CLINIC SETTING
    Judith Shlay; Fiscal Year: 1999
    ..3%. Such a program has the potential of addressing comprehensive reproductive care from the context of the STD clinic and, if successful, may offer a useful model for other STD programs to consider. ..
  23. HORMONAL CONTRACEPTON &RISK OF HIV ACQUISITION
    Elaine D Eaker; Fiscal Year: 2009
    ....
  24. FEMORAL OSTEOPOROSIS IN ELDERLY WOMEN
    Susan Greenspan; Fiscal Year: 1999
    ..Data derived from this study should provide the basic for an effective intervention to stabilize or increase femoral bone mass and reserve architectural integrity in elderly women. ..
  25. ER beta selective agonist coronary protection-menopause
    R Hermsmeyer; Fiscal Year: 2005
    ..The new ERbetaA is to be contrasted with PremPro(r) (oral conjugated equine estrogens plus medroxyprogesterone acetate) which failed to provide cardiovascular protection in the Women's Health Initiative. ..
  26. Progestin Actions in the Primate Breast and Uterus
    Charles Wood; Fiscal Year: 2009
    ..This work will have immediate public health relevance to postmenopausal women seeking the safest form of hormone therapy. ..
  27. DIHYDRODIOL DEHYDROGENASE & PAH DETOXIFICATION
    TREVOR PENNING; Fiscal Year: 1992
    ....
  28. Hormone Replacement and Cerebral Glucose Metabolism
    John Woodard; Fiscal Year: 2000
    ....
  29. Progestin Levels and Inflammation in Postmenopause
    Peifeng Hu; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  30. ADOLESCENT MISCONCEPTIONS ABOUT HORMONAL CONTRACEPTION
    LIANA CLARK; Fiscal Year: 2003
    ..Increased usage and improved compliance with Depo-Provera, Norplant and the oral contraceptive pill will result in an overall decrease in the rate of unintended adolescent pregnancy. ..
  31. HORMONE REPLACEMENT AND METABOLIC CARDIOVASCULAR RISK
    Cynthia Sites; Fiscal Year: 2003
    ..In addition, our study may allow physicians to target hormone replacement to women with specific body compositions. ..
  32. EXERCISE, ESTROGEN AND AGING--CARDIAC FUNCTION IN WOMEN
    ROBERT SPINA; Fiscal Year: 1999
    ..Blood volume will be measured by determining red cell and plasma volumes by standard radionuclide techniques. Arterial stiffness will be evaluated by measurement of pulse wave velocity. ..
  33. INJECTABLE CONTRACEPTIVES AND BONE ULTRASOUND MEASURES
    Lynn Rosenberg; Fiscal Year: 2005
    ..Millions of women worldwide have used IPCs. Given the heavy burden of osteoporotic fractures in elderly women, it is of public health importance to determine whether IPCs have an adverse effect on bone. ..
  34. Modulation of Estrogen-regulated Genes by PR Isoforms
    DJUANA HARVELL; Fiscal Year: 2006
    ..Together, these experiments will define how PRs influence +E signaling in breast cancers. ..
  35. Progestogen Inhibition of Ovarian Cancer Cell Metastasis
    William Murdoch; Fiscal Year: 2003
    ....
  36. HORMONES, THE BRAIN AND BEHAVIOR
    Doris Zumpe; Fiscal Year: 1999
    ..Comparisons between monkeys and rats will help elucidate a previously identified species difference in mating-induced c-fos expression. ..
  37. CORONARY ANGIOGRAPHIC TRIAL OF ESTROGEN THERAPY
    HOWARD HODIS; Fiscal Year: 2001
    ..Hard data on this critical issue is needed for physicians to weigh the risk/benefit concerning HRT in postmenopausal women in order to set practice patterns. ..
  38. Estrogen Modulates Injury-Induced Inflammation
    Suzanne Oparil; Fiscal Year: 2007
    ..These fundamental mechanistic studies will enhance our understanding of the pathobiology of vascular disease, particularly as it occurs in aging women, and will provide the basis for development of novel therapeutic strategies. ..
  39. RANDOMIZED TRIAL OF ESTROGEN-ATHEROSCLEROSIS REGRESSION
    Thomas Clarkson; Fiscal Year: 1992
    ....
  40. Effect of hormonal contraception on bone mineral density
    Abbey Berenson; Fiscal Year: 2005
    ..Ultimately, this study will determine which women, if any, are placed at increased risk of osteopenia or osteoporosis as a result of using these hormonal contraceptives during their reproductive years. ..
  41. DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTS
    Barbara Cromer; Fiscal Year: 2003
    ..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
  42. Depo-provera & BMD: Continuing Observations
    M Clark; Fiscal Year: 2005
    ..The longitudinal design will be continued, maintaining all methods and protocols employed in the parent study. ..
  43. The effect of nonoxynol-9 on human endometrium
    John Jain; Fiscal Year: 2005
    ..The results of this study will provide important preliminary information on the role of microbicides on endometrial toxicity and may help guide future research priorities. ..
  44. Ectopic Pregnancy: Assessing Long-Term Trends in Rates and Risk Factors
    Delia Scholes; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  45. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2006
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  46. Oral Contraceptive Use and Bone Density in Young Women
    Delia Scholes; Fiscal Year: 2008
    ..abstract_text> ..
  47. Prevention of Weight Gain in Young Adults
    Mark Espeland; Fiscal Year: 2009
    ..This approach shows promise for reducing weight gain and thereby improving long-term cardiovascular health. (End of Abstract) ..
  48. Seniors Health and Activity Research Program Pilot (SHARP-P)
    Mark Espeland; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  49. COOPERATIVE MULTICENTER REPRODUCTIVE MEDICINE NETWORK
    Bruce Carr; Fiscal Year: 2004
    ..In summary, the reproductive endocrinology research team is experienced in multi- center clinical trials and is committed to collaborative participation consistent with the goals of the RMU network. ..
  50. Thrombosis Gene Polymorphisms and Early CHD Risk in HERS
    David Herrington; Fiscal Year: 2004
    ....
  51. Soy and Estrogen Interactions in the Breast
    J Cline; Fiscal Year: 2009
    ..The proposed work will provide a unique view of an otherwise inaccessible period of breast development in a primate model with high genetic and physiologic similarity to human beings. ..
  52. PHYSIOLOGY OF REPRODUCTION
    Bruce Carr; Fiscal Year: 2003
    ..D. and 5 M.D. trainees, on average) and 2 predoctoral students matriculating for the Ph.D. degree. During the past 10 years, 45 postdoctoral and predoctoral trainees have been supported by this grant. ..
  53. A MECHANISTIC STUDY OF SKELETAL ACTIONS OF 1-34hPTH
    Robert Lindsay; Fiscal Year: 2009
    ..abstract_text> ..
  54. Estrogen Receptor Variance and CHD Risk in HERS
    David Herrington; Fiscal Year: 2004
    ..In addition, this information could lead to fundamentally important new knowledge about mechanisms of estrogen action, regulation of HDL cholesterol, and pathogenesis of CHD. ..
  55. Effects of Dietary Soy on Biomarkers in Prostate Cancer
    J Cline; Fiscal Year: 2004
    ..abstract_text> ..
  56. UCSF-KAISER WOMEN'S HEALTH INTERDISCIPLINARY SCHOLARSHIP
    Deborah Grady; Fiscal Year: 2004
    ..Our goal is to create a model national resource for training successful investigators in women's health. ..
  57. Progesterone, GABA Receptors and Cell Survival
    Meharvan Singh; Fiscal Year: 2005
    ..abstract_text> ..
  58. Estrogen Receptor Variants,HDL, and Atherosclerosis
    David Herrington; Fiscal Year: 2005
    ....
  59. Machine Learning to Identify Complex Interactions in Genome-Wide Association Data
    David Herrington; Fiscal Year: 2009
    ..Determining specific genetic and/or environmental factors that influence a person's risk of disease may help doctors reduce risk for disease and reveal new treatments for disease. (End of Abstract) ..
  60. A DIAGNOSTIC TEST TO ASSESS RISK ASSOCIATED WITH ANDROGEN THERAPY
    Meharvan Singh; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  61. Intrauterine Inflammation & Adverse Neurological Outcome
    Michal A Elovitz; Fiscal Year: 2010
    ..abstract_text> ..
  62. Membrane Androgen Receptors in Neuroprotection
    Meharvan Singh; Fiscal Year: 2007
    ..unreadable] [unreadable]..